Literature DB >> 7669481

Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.

R Fogari1, A Zoppi, G D Malamani, G Marasi, A Vanasia, G Villa.   

Abstract

1. In order to evaluate whether treatment with different antihypertensive drugs would affect plasma fibrinogen levels, 118 mild to moderate essential hypertensive subjects, all males, aged 18 to 65 years, were randomly treated with amlodipine 10 mg, atenolol 100 mg, hydrochlorothiazide 25 mg or lisinopril 20 mg, all given once daily for 8 weeks. 2. Before and after 8 weeks' treatment, blood pressure (BP), heart rate (HR), fibrinogen, total cholesterol (TC), HDL-C, LDL-C, triglycerides (TG), plasma glucose, plasma uric acid, serum creatinine and serum potassium were evaluated. 3. All four medications significantly reduced BP values, although the BP lowering effect of lisinopril, amlodipine and atenolol was significantly greater compared with that of hydrochlorothiazide. 4. Plasma fibrinogen levels were unaffected by atenolol, hydrochlorothiazide and amlodipine, whereas they were significantly decreased by lisinopril (-11.2%, P = 0.002). This fibrinogen lowering effect was more evident in smokers (-17.7%) than in non smokers (-7.4%). 5. Atenolol and amlodipine did not significantly affect plasma lipids, hydrochlorothiazide increased TC, LDL-C and TG and reduced HDL-C; lisinopril increased HDL-C and decreased TC and LDL-C. 6. Hydrochlorothiazide increased plasma glucose and uric acid concentrations, which were unaffected by the other drugs. The diuretic also reduced serum potassium. 7. The results of this study indicate that lisinopril reduces levels of plasma fibrinogen and confirm that different antihypertensive drugs may elicit different metabolic effects, which may variously influence the overall risk profile of the hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669481      PMCID: PMC1365052          DOI: 10.1111/j.1365-2125.1995.tb04482.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  38 in total

Review 1.  Lowering the plasma fibrinogen concentration with drugs.

Authors:  E Ernst
Journal:  Clin Pharm       Date:  1992-11

2.  [Rapid physiological coagulation method in determination of fibrinogen].

Authors:  A CLAUSS
Journal:  Acta Haematol       Date:  1957-04       Impact factor: 2.195

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  [Enzymatic determination of total cholesterol in serum (author's transl)].

Authors:  P Röschlau; E Bernt; W Gruber
Journal:  Z Klin Chem Klin Biochem       Date:  1974-09

5.  Rheological aspects of cerebrovascular disease.

Authors:  E Ott; F Fazekas; M Tschinkel; G Bertha; H Lechner
Journal:  Eur Neurol       Date:  1983       Impact factor: 1.710

6.  Relation between extent of coronary artery disease and blood viscosity.

Authors:  G D Lowe; M M Drummond; A R Lorimer; I Hutton; C D Forbes; C R Prentice; J C Barbenel
Journal:  Br Med J       Date:  1980-03-08

7.  Fibrinogen and low density lipoprotein in the development of cerebral atherosclerosis.

Authors:  S Sadoshima; K Tanaka
Journal:  Atherosclerosis       Date:  1979-10       Impact factor: 5.162

8.  Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study.

Authors:  A J Lee; G D Lowe; M Woodward; H Tunstall-Pedoe
Journal:  Br Heart J       Date:  1993-04

9.  Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.

Authors:  E Ernst; K L Resch
Journal:  Ann Intern Med       Date:  1993-06-15       Impact factor: 25.391

10.  Exercise, fibrinogen, and other risk factors for ischaemic heart disease. Caerphilly Prospective Heart Disease Study.

Authors:  P C Elwood; J W Yarnell; J Pickering; A M Fehily; J R O'Brien
Journal:  Br Heart J       Date:  1993-02
View more
  7 in total

1.  Long-term efficacy and tolerability of a fixed-dose combination of antihypertensive agents: an open-label surveillance study in China.

Authors:  Yiqun Wu; Yonghua Hu; Xun Tang; Liu He; Tao Ren; Qiushan Tao; Xueying Qin; Ningling Sun; Hongyi Wang; Weihua Cao; Tao Wu; Siyan Zhan; Jin Wang; Weihua Chen; Liming Li
Journal:  Clin Drug Investig       Date:  2011-11-01       Impact factor: 2.859

Review 2.  Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.

Authors:  K L Goa; J A Balfour; G Zuanetti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 3.  Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.

Authors:  H D Langtry; A Markham
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

4.  Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.

Authors:  Amy I Lynch; Eric Boerwinkle; Barry R Davis; Charles E Ford; John H Eckfeldt; Catherine Leiendecker-Foster; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2009-06       Impact factor: 2.089

Review 5.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 6.  Thiazide Diuretic-Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials.

Authors:  Jill J Hall; Dean T Eurich; Danielle Nagy; Lisa Tjosvold; John-Michael Gamble
Journal:  J Gen Intern Med       Date:  2020-03-10       Impact factor: 5.128

7.  Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.

Authors:  William Phillips; Linda B Piller; Jeff D Williamson; Jeffrey Whittle; Syed Z A Jafri; Charles E Ford; Paula T Einhorn; Suzanne Oparil; Curt D Furberg; Richard H Grimm; Michael H Alderman; Barry R Davis; Jeffrey L Probstfield
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-08-07       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.